Phoenix 24
Fake drugs are becoming a public health risk.
Berlin, May 2026. German customs authorities have warned of a growing rise in counterfeit medicines entering European markets, exposing a criminal economy that now moves through online sales, informal suppliers and cross-border logistics. The warning places falsified pharmaceuticals at the center of a broader public health concern, not merely a customs or consumer fraud issue.
Authorities say counterfeit medicines are especially dangerous because they can contain incorrect ingredients, unsafe substances or ineffective dosages. The risk increases when patients buy treatments outside regulated medical channels, often attracted by lower prices, quick access or discreet delivery. In this market, the appearance of legitimacy can become part of the threat.
The problem is no longer limited to lifestyle products or marginal online offers. European enforcement bodies have repeatedly warned that criminal groups are expanding into higher-demand medicines, using digital platforms to reach consumers directly. That shift turns pharmaceutical falsification into a strategic vulnerability for health systems.
For Europe, the challenge is structural. Globalized supply chains, online commerce and fragmented enforcement create openings that organized networks can exploit faster than regulators can close them. Customs seizures may interrupt flows, but they do not eliminate the demand that sustains the market.
The rise of counterfeit medicine reveals a deeper crisis of trust. When patients cannot distinguish between a safe treatment and a dangerous imitation, public health becomes dependent not only on hospitals and pharmacies, but on the integrity of logistics, regulation and digital marketplaces. In that sense, fake medicine is no longer a hidden crime; it is a test of Europe’s capacity to defend the credibility of its own health infrastructure.
Hechos que no se doblan. / Facts that do not bend.